One qualifier I brought up before is frequency of dosing. This calculation assumes that those treated get a treatment course every year. That may not be the case, and we don’t have data on the durability as yet. But suppose on average the treatment is applied every second year. That would halve the revenue.
I still like those numbers.
Potential Financial Implications of Yesterday's Results, page-4
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.0¢ | 21.5¢ | $78.13K | 350.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64880 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 43479 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |